Fianlimab is an investigational medication being studied for its potential to help treat melanoma, a type of skin cancer. In this trial, it is used in combination with another medication to see if it can improve treatment outcomes for patients with melanoma that can be surgically removed.

Cemiplimab is a medication used to treat certain types of skin cancer, including melanoma. It works by helping the immune system recognize and attack cancer cells. In this trial, it is used both alone and in combination with fianlimab to evaluate its effectiveness in treating melanoma.

Pembrolizumab is a medication that helps the immune system fight cancer by blocking a specific pathway that cancer cells use to hide from immune cells. In this trial, it is used as a comparison to the combination of fianlimab and cemiplimab to determine which treatment is more effective for patients with melanoma that can be surgically removed.

Melanoma – Melanoma is a type of skin cancer that begins in the melanocytes, which are the cells responsible for producing the pigment melanin. It often appears as a new mole or a change in an existing mole, and it can be identified by its irregular shape, multiple colors, and larger size. Melanoma can grow quickly and has the potential to spread to other parts of the body if not detected early. The progression of melanoma involves the cancer cells invading deeper layers of the skin and potentially entering the lymphatic system or bloodstream. This spread can lead to the formation of new tumors in distant organs, a process known as metastasis. Early detection and monitoring of changes in the skin are crucial in managing the progression of melanoma.